TC-G 1005 (25-100 mg/kg; a single p.o.) stimulates GLP-1 secretion in imprinting control region (ICR) mice[1].
TC-G 1005 (50 mg/kg; a single p.o.) causes a 49% reduction in blood glucose AUC0-120 min in ICR mice[1].
TC-G 1005 (50 mg/kg; a single p.o.) signicantly reduces blood glucose at 4, 6, 10, and 24 h in db/db mice[1].
TC-G 1005 (5 mg/kg; p.o.) exhibits rather low plasma exposure, with a Cmax of 56 ng/mL and a t1/2 of 1.5 in rats[1].
| Animal Model: | Male ICR mice[1] |
| Dosage: | 25, 50, 100 mg/kg |
| Administration: | A single p.o. |
| Result: | Increased the plasma active GLP-1 levels by 31, 96, and 282% at doses of 25, 50, and 100 mg/kg, respectively. |